MEDGENERA
  • Sections
    • NEWLY PUBLISHED
    • News from Asia-pacific
    • News from Europe
    • News from USA
    • MEDGENERA ORIGINAL
    • ASSESSMENT
    • MARKET INSIGHTS
    • DRUG TRIAL
    • PROGRESSIVE REVIEW
    • APPS & IMPLANTS
  • About us
  • Plans
  • Education
  • Get Online Training
  • Login
  • Webinar
0
  • Login
  • Get 1-Free month
  • Online Course
  • About us
  • BIORISE
  • Plans
  • BUSINESS
  • CAREER
  • HEALTHCARE & MEDICINE
  • IN-DEPTH STORIES
  • KNOWLEDGE CENTRE
  • MEDGENERA EXCLUSIVE
  • NEWLY PUBLISHED
  • News from Asia-pacific
  • News from Europe
  • News from USA
  • RESOURCE CENTRES
  • TECHNOLOGY

Category: News from USA

Proportion
Vikash KumarApril 23, 2018

This Cancer Biotech Startup Raises Over 40% Higher in IPO than Proposed Goal

The cancer startup develops novel immunotherapies that target the immune-suppressive tumor microenvironment to attack cancer. The company is developing immuno-oncology drugs which could be combined with existing immunotherapies to enhance the efficiency of detecting and killing cancer cells.

Proportion
Tiash SahaApril 17, 2018

Genprex Raises $6.4 M in IPO, Could Bring “Game-Changing” Immuno-Gene Therapy for Advanced Lung Cancer

Genprex raised $6.4 million in IPO at a share price of $5. Unlike most of the commercial blockbuster lung cancer immunotherapies, its unique lead candidate, Oncoprex® targets advanced lung cancer treatment.

Proportion
Tiash SahaMarch 19, 2018

FDA Grants Orphan Drug Status to PET imaging agent CLR 131 for a Rare Cancer

Positron Emission Tomography (PET) imaging makes the cancer detection more sensitive and less toxic to the normal cells. PET imaging ...

Proportion
Vikash KumarMarch 19, 2018

Infographics- Biotech in IPO’18 (RCUS)

Illustrations: Medgenera DATALABS

Proportion
Tiash SahaMarch 14, 2018

AI-Based Software EyeArt™ in Smartphone Could Prevent Vision Loss in 90% Diabetic People

KEY POINTS One in five diabetic Indians is at risk of developing diabetic retinopathy, which can lead to blindness. Eyenuk’s ...

Proportion
Tiash SahaFebruary 22, 2018

Gilead Company, Kite Collaborates with Sangamo to Develop Engineered Cell Therapies for Cancer

Gene therapy company, Sangamo Therapeutics collaborated with Gilead Sciences subsidiary, Kite Pharma to develop next-generation ex vivo (out of the ...

Proportion
Tiash SahaFebruary 14, 2018

Astellas Buys Universal Cells in $102.5M Deal to Develop Universal Donor Cells

Japanese pharma company, Astellas acquired the US-based biotech firm, Universal Cells. Astellas will pay up to $102.5 million upfront plus ...

Proportion
Tiash SahaFebruary 13, 2018

Novartis Ties with Cancer Targeted Technology to Improve Diagnostics for Prostate Cancer

Novartis’ nuclear medicine subsidiary, Advanced Accelerator Applications (AAA) inked a global partnership with US-based Cancer Targeted Technology (CTT) for the ...

Proportion
Tiash SahaFebruary 12, 2018

Pfizer’s Lorlatinib Gets FDA Priority Review Status to Treat ALK-Positive Lung Cancer

KEY POINTS Lorlatinib is a next-generation ALK/ROS1 tyrosine kinase inhibitor.  Last year, lorlatinib had received Breakthrough Therapy designation from the ...

Proportion
Tiash SahaFebruary 12, 2018

Amicus’ Fabry Disease drug, Migalastat Gets Ready for Approval in the US

Rare diseases company, Amicus Therapeutics’ New Drug Application (NDA) for migalastat (migalastat HCl), for filing under priority review is accepted ...

  • 1
  • 2
Privacy Policy Terms Payment Policy Education Contact Us About us